---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-016712"
form_type: "8-K"
ticker: null
cik: "0001840748"
company_name: "LAVA Therapeutics NV"
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:56:46.238136+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# LAVA Therapeutics cuts workforce ~30%, starts strategic review with advisor

## Summary
- Workforce reduction of approx. 30%; expects $0.5M one-time costs, mostly Q1 2025.
- Board initiated strategic review to evaluate sale, merger, licensing, or other options.
- Cash, cash equivalents & investments $76.6M as of Dec 31, 2024 (unaudited).
- Will continue Phase 1 LAVA-1266 trial in AML/MDS and support Pfizer, J&J partnerships.

## SEC filing metadata
- accession: 0001104659-25-016712
- form_type: 8-K
- cik: 0001840748
- company_name: LAVA Therapeutics NV
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840748/000110465925016712/0001104659-25-016712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840748/000110465925016712/tm257490d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-016712
- JSON: https://secwatch.observer/filing/0001104659-25-016712.json
- Plain text: https://secwatch.observer/filing/0001104659-25-016712.txt

## Key facts
- Restructurings & Charges
  LAVA Therapeutics NV announced a restructuring with charges of approximately $0.5 million (approximately 30%).
  - Type: restructuring
  - Charge: approximately $0.5 million
  - Headcount: approximately 30%
  source text: On February 20, 2025, LAVA Therapeutics N.V. (the “Company”) adopted a restructuring plan to extend its capital resources in connection with initiating a process to evaluate strategic alternatives. As part of the restructuring plan, the Company is planning a workforce reduction of approximately 30%. The Company anticipates that the reduction in workforce will be completed by July 31, 2025. The Company estimates that it will incur approximately $0.5 million of one-time termination benefits and related taxes related to the workforce reduction, with the majority of such costs to be incurred in the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840748/000110465925016712/0001104659-25-016712-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.